Journal of International Oncology››2019,Vol. 46››Issue (5): 303-306.doi:10.3760/cma.j.issn.1673-422X.2019.05.011
Previous ArticlesNext Articles
Sun Yueqin, Li Aimin, Luo Yue, Song Zhenghui, Zhuang Xuefen, Dai Guanqi, Liu Xinhui
Received:
2019-02-22Online:
2019-05-08Published:
2019-06-14Contact:
Liu Xinhui E-mail:liuxinhui89@126.comSupported by:
National Natural Science Foundation of China (81572797); Natural Science Foundation of Guangdong Province of China (2016A030311015); Science and Technology Project of Guangzhou City of China (201604020009)
Sun Yueqin, Li Aimin, Luo Yue, Song Zhenghui, Zhuang Xuefen, Dai Guanqi, Liu Xinhui. Efficacy prediction and molecular mechanism of thyroid hormone levels and multi-target TKI therapy for renal cell carcinoma and hepatocellular carcinoma[J]. Journal of International Oncology, 2019, 46(5): 303-306.
[1] Shi XZ, Jin X, Xu P, et al. Relationship between breast cancer and levels of serum thyroid hormones and antibodies: a metaanalysis[J]. Asian Pac J Cancer Prev, 2014, 15(16): 6643-6647. [2] Prinzi N, Sorrenti S, Baldini E, et al. Association of thyroid diseases with primary extrathyroidal malignancies in women: results of a cross-sectional study of 6,386 patients[J]. PLoS One, 2015, 10(3): e122958. DOI: 10.1371/journal.pone.0122958. [3] Pinter M, Haupt L, Hucke F, et al. The impact of thyroid hormones on patients with hepatocellular carcinoma[J]. PLoS One, 2017, 12(8): e0181878. DOI: 10.1371/journal.pone.0181878. [4] Borriello A, Caldarelli I, Bencivenga D, et al. Tyrosine kinase inhibitors and mesenchymal stromal cells: effects on selfrenewal, commitment and functions[J]. Oncotarget, 2017, 8(3): 5540-5565. DOI: 10.18632/oncotarget.12649. [5] Jiao Q, Bi L, Ren Y, et al. Advances in studies of tyrosine kinase inhibitors and their acquired resistance[J]. Mol Cancer, 2018, 17(1): 36. DOI: 10.1186/s12943-018-0801-5. [6] Qin S, Li A, Yi M, et al. Recent advances on antiangiogenesis receptor tyrosine kinase inhibitors in cancer therapy[J]. J Hematol Oncol, 2019, 12(1): 27. DOI: 10.1186/s13045-019-0718-5. [7] Beukhof CM, van Doorn L, Visser TJ, et al. Sorafenibinduced changes in thyroid hormone levels in patients treated for hepatocellular carcinoma[J]. J Clin Endocrinol Metab, 2017, 102(8): 2922-2929. DOI: 10.1210/jc.2016-4025. [8] Mondello P, Mian M, Pitini V, et al. Thyroid hormone autoantibodies: are they a better marker to detect early thyroid damage in patients with hematologic cancers receiving tyrosine kinase inhibitor or immunoregulatory drug treatments?[J]. Curr Oncol, 2016, 23(3): e165-e170. DOI: 10.3747/co.23.3026. [9] Motzer RJ, Jonasch E, Agarwal N, et al. Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2017, 15(6): 804-834. DOI: 10.6004/jnccn.2017.0100. [10] Wolter P, Stefan C, Decallonne B, et al. Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients with advanced renal cell cancer (RCC)[J]. J Clin Oncol, 2008, 26(15_Suppl): 5126. DOI: 10.1200/jco.2008.26.15_suppl.5126. [11] Riesenbeck LM, Bierer S, Hoffmeister I, et al. Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib[J]. World J Urol, 2011, 29(6): 807-813. DOI: 10.1007/s00345-010-0627-2. [12] Nearchou A, Valachis A, Lind P, et al. Acquired hypothyroidism as a predictive marker of outcome in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: a literature-based meta-analysis[J]. Clin Genitourin Cancer, 2015, 13(4): 280-286. DOI: 10.1016/j.clgc.2014.10.002. [13] Lechner MG, Vyas CM, Hamnvik OR, et al. Hypothyroidism during tyrosine kinase inhibitor therapy is associated with longer survival in patients with advanced nonthyroidal cancers[J]. Thyroid, 2018, 28(4): 445-453. DOI: 10.1089/thy.2017.0587. [14] Wang T, Xia L, Ma S, et al. Hepatocellular carcinoma: thyroid hormone promotes tumorigenicity through inducing cancer stem-like cell self renewal[J]. Sci Rep, 2016, 6: 25183. DOI: 10.1038/srep25183. [15] Zhang N, Jin W, Zhou S, et al. Hypothyroidism is associated with worse outcomes of hepatocellular carcinoma patients after liver transplantation[J]. Cancer Med, 2018, 7(12): 5870-5878. DOI: 10.1002/cam4.1797. [16] Chu YD, Lin KH, Huang YH, et al. A novel thyroid function index associated with opposite therapeutic outcomes in advanced hepatocellular carcinoma patients receiving chemotherapy or sorafenib[J]. Asia Pac J Clin Oncol, 2018, 14(5): e341-e351. DOI: 10.1111/ajco.12983. [17] BudaNowak A, Kucharz J, Dumnicka P, et al. Sunitinibinduced hypothyroidism predicts progressionfree survival in metastatic renal cell carcinoma patients[J]. Med Oncol, 2017, 34(4): 68. DOI: 10.1007/s12032-017-0928-z. [18] White PT, Cohen MS. The discovery and development of sorafenib for the treatment of thyroid cancer[J]. Expert Opin Drug Discov, 2015, 10(4): 427-439. DOI: 10.1517/17460441.2015.1006194. [19] De Falco V, Carlomagno F, Li HY, et al. The molecular basis for RET tyrosinekinase inhibitors in thyroid cancer[J]. Best Pract Res Clin Endocrinol Metab, 2017, 31(3): 307-318. DOI: 10.1016/j.beem.2017.04.013. [20] Drui D, Illouz F, Do Cao C, et al. Expert opinion on thyroid complications of new anticancer therapies: tyrosine kinase inhibitors[J]. Ann Endocrinol (Paris), 2018, 79(5): 569-573. DOI: 10.1016/j.ando.2018.07.003. [21] Shu M, Zai X, Zhang B, et al. Hypothyroidism side effect in patients treated with sunitinib or sorafenib: clinical and structural analyses[J]. PLoS One, 2016, 11(1): e0147048. DOI: 10.1371/journal.pone.0147048. [22] Lin HY, Chin YT, Yang YC, et al. Thyroid hormone, cancer, and apoptosis[J]. Compr Physiol, 2016, 6(3): 1221-1237. DOI: 10.1002/cphy.c150035. [23] Czarnecka AM, Matak D, Szymanski L, et al. Triiodothyronine regulates cell growth and survival in renal cell cancer[J]. Int J Oncol, 2016, 49(4): 1666-1678. DOI: 10.3892/ijo.2016.3668. [24] Frau C, Loi R, Petrelli A, et al. Local hypothyroidism favors the progression of preneoplastic lesions to hepatocellular carcinoma in rats[J]. Hepatology, 2015, 61(1): 249-259. DOI: 10.1002/hep.27399. [25] Perra A, Plateroti M, Columbano A. T3/TRs axis in hepatocellular carcinoma: new concepts for an old pair[J]. Endocr Relat Cancer, 2016, 23(8): R353-R369. DOI: 10.1530/ERC-16-0152. [26] MartinezIglesias O, GarciaSilva S, Tenbaum SP, et al. Thyroid hormone receptor beta1 acts as a potent suppressor of tumor invasiveness and metastasis[J]. Cancer Res, 2009, 69(2): 501-509. DOI: 10.1158/0008-5472.CAN-08-2198. [27] Chung IH, Chen CY, Lin YH, et al. Thyroid hormonemediated regulation of lipocalin 2 through the Met/FAK pathway in liver cancer[J]. Oncotarget, 2015, 6(17): 15050-15064. DOI: 10.18632/oncotarget.3670. [28] Wu SM, Cheng WL, Liao CJ, et al. Negative modulation of the epigenetic regulator, UHRF1, by thyroid hormone receptors suppresses liver cancer cell growth[J]. Int J Cancer, 2015, 137(1): 37-49. DOI: 10.1002/ijc.29368. [29] Hercbergs AA, Goyal LK, Suh JH, et al. Propylthiouracilinduced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase Ⅰ/Ⅱ study[J]. Anticancer Res, 2003, 23(1B): 617-626. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||